Alaunos Therapeutics, Inc. Interest Expense
Alaunos Therapeutics, Inc. (TCRT) reported Interest Expense of $0 for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-14.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-08-14
- Alaunos Therapeutics, Inc. interest expense for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. interest expense for fiscal 2023 was $1.92M, a 39.09% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. interest expense for fiscal 2022 was $3.15M, a 165.26% increase from fiscal 2021.
- Alaunos Therapeutics, Inc. interest expense for fiscal 2021 was $1.19M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2024-08-14 | $0.00 derived: sum of 4 quarters · filed 2024-08-14 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-05-15 | $0.00 derived: sum of 3 quarters · filed 2024-05-15 | $1.07M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $1.07M derived: sum of 3 quarters · filed 2024-08-14 | $1.92M 10-K · filed 2024-04-01 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | $1.07M derived: sum of 2 quarters · filed 2024-08-14 | $1.92M 10-Q · filed 2023-11-14 | $2.81M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-06-30 | $1.07M 10-Q · filed 2024-08-14 | $1.92M 10-Q · filed 2024-08-14 | $2.81M derived: sum of 3 quarters · filed 2024-08-14 | $3.65M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $853.00K 10-Q · filed 2024-05-15 | $1.74M derived: sum of 2 quarters · filed 2024-05-15 | $2.58M derived: sum of 3 quarters · filed 2024-05-15 | $3.32M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $888.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $1.73M derived: sum of 2 quarters · filed 2024-04-01 | $2.47M derived: sum of 3 quarters · filed 2024-04-01 | $3.15M 10-K · filed 2024-04-01 |
| 2022-09-30 | $841.00K 10-Q · filed 2023-11-14 | $1.58M derived: sum of 2 quarters · filed 2023-11-14 | $2.27M 10-Q · filed 2023-11-14 | $3.01M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $740.00K 10-Q · filed 2023-08-14 | $1.43M 10-Q · filed 2023-08-14 | $2.17M derived: sum of 3 quarters · filed 2023-08-14 | $2.61M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $683.00K 10-Q · filed 2023-05-10 | $1.43M derived: sum of 2 quarters · filed 2023-05-10 | $1.87M derived: sum of 3 quarters · filed 2023-05-10 | $1.87M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $745.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $1.19M derived: sum of 2 quarters · filed 2023-03-07 | $1.19M derived: sum of 3 quarters · filed 2023-03-07 | $1.19M 10-K · filed 2023-03-07 |
| 2021-09-30 | $444.00K 10-Q · filed 2022-11-14 | $444.00K derived: sum of 2 quarters · filed 2022-11-14 | $444.00K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |